Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00052494
First received: January 24, 2003
Last updated: February 19, 2009
Last verified: August 2005

January 24, 2003
February 19, 2009
April 2003
February 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00052494 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase I Study Of STI 571 (Gleevec) In Combination With Cisplatin/Irinotecan In Patients With Extensive Stage Small Cell Lung Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining more than one chemotherapy drug with imatinib mesylate may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining cisplatin, irinotecan, and imatinib mesylate in treating patients who have extensive-stage small cell lung cancer.

OBJECTIVES:

  • Determine the maximum tolerated dose of imatinib mesylate when administered with cisplatin and irinotecan in patients with extensive stage small cell lung cancer.
  • Determine the recommended phase II dose of imatinib mesylate in patients treated with this regimen.
  • Determine the response rate, median duration of response, progression-free survival, median survival, and overall survival of patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of imatinib mesylate.

Patients receive cisplatin IV over 1 hour on day 1 and irinotecan IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a maximum of 4 courses. Patients also receive oral imatinib mesylate daily continually for one week prior to, during, and after chemotherapy in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at the recommended phase II dose (one dose level below the MTD).

PROJECTED ACCRUAL: A total of 12-24 patients will be accrued for this study within 1-2 years.

Interventional
Phase 1
Primary Purpose: Treatment
Lung Cancer
  • Drug: cisplatin
  • Drug: imatinib mesylate
  • Drug: irinotecan hydrochloride
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
February 2009   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed extensive stage small cell lung cancer

    • Incurable but amenable to treatment with chemotherapy
    • c-kit positive by immunohistochemistry of original biopsy or other metastatic site
  • At least one unidimensionally measurable lesion

    • > 20 mm by conventional techniques or > 10 mm by spiral CT scan
    • No prior radiotherapy to target measurable lesion(s), unless there is documented disease progression
  • No known brain metastases

PATIENT CHARACTERISTICS:

Age

  • Not specified

Performance status

  • ECOG 0-1 OR
  • Karnofsky 70-100%

Life expectancy

  • More than 6 weeks

Hematopoietic

  • WBC ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3

Hepatic

  • Bilirubin normal
  • AST and/or ALT ≤ 2.5 times upper limit of normal

Renal

  • Creatinine normal OR
  • Creatinine clearance ≥ 60 mL/min

Cardiovascular

  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia

Gastrointestinal

  • No concurrent untreated upper gastrointestinal bleeding that has not been fully investigated
  • No gastrointestinal disease that would impair drug absorption

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception prior to, during, and for 3 months after study participation
  • No history of ototoxicity
  • No history of peripheral neuropathy
  • No traumatic injury within the past 21 days
  • No ongoing or active infection
  • No other concurrent significant medical condition that would preclude study participation
  • No concurrent psychiatric condition or social situation that would preclude study compliance
  • No other malignancy within the past 5 years except treated nonmelanoma skin cancer, carcinoma in situ, or stage A prostate cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • See Disease Characteristics
  • No prior chemotherapy
  • No other concurrent chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • See Disease Characteristics
  • More than 4 weeks since prior radiotherapy
  • No prior radiotherapy to more than 25% of marrow

Surgery

  • More than 3 weeks since prior major surgery
  • No prior surgical procedure impairing absorption

Other

  • No prior c-kit-targeted therapy
  • No concurrent therapeutic dose of warfarin

    • Mini-dose warfarin for prophylaxis and low-molecular weight heparin allowed
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No other concurrent investigational agents
  • No concurrent amifostine
  • No other concurrent anticancer therapy
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00052494
CDR0000258487, PMH-PHL-008, NCI-5684
Not Provided
Not Provided
Princess Margaret Hospital, Canada
National Cancer Institute (NCI)
Study Chair: Mark D. Vincent, MD London Regional Cancer Program at London Health Sciences Centre
National Cancer Institute (NCI)
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP